接受美沙酮和蛋白酶抑制剂洛匹那韦-利托那韦治疗的患者未出现阿片类药物戒断症状。
Absence of opioid withdrawal symptoms in patients receiving methadone and the protease inhibitor lopinavir-ritonavir.
作者信息
Clarke Susan, Mulcahy Fiona, Bergin Colm, Reynolds Helen, Boyle Nicola, Barry Michael, Back David J
机构信息
GenitoUrinary Medicine and Infectious Diseases Clinic, St. James's Hospital, Dublin, Ireland.
出版信息
Clin Infect Dis. 2002 Apr 15;34(8):1143-5. doi: 10.1086/339541. Epub 2002 Mar 19.
A study was designed to determine the interactions, both clinical and pharmacokinetic, between methadone and lopinavir-ritonavir. Results demonstrated a 36% reduction in the methadone area under the plasma concentration-time curve after the introduction of lopinavir-ritonavir, with no coincident symptoms of opioid withdrawal and no requirement for methadone dose adjustment.
一项研究旨在确定美沙酮与洛匹那韦-利托那韦之间的临床和药代动力学相互作用。结果表明，引入洛匹那韦-利托那韦后，美沙酮血浆浓度-时间曲线下面积降低了36%，同时没有出现阿片类药物戒断症状，也无需调整美沙酮剂量。
Zotero 插件